A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

PHASE3CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2015

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

dolutegravir

50 mg twice daily

Trial Locations (89)

1000

GSK Investigational Site, Brussels

1150

GSK Investigational Site, Lisbon

3030

GSK Investigational Site, Coimbra

4000

GSK Investigational Site, Liège

10011

GSK Investigational Site, New York

10016

GSK Investigational Site, New York

10149

GSK Investigational Site, Turin

10461

GSK Investigational Site, The Bronx

10467

GSK Investigational Site, The Bronx

10595

GSK Investigational Site, Valhalla

12209

GSK Investigational Site, Albany

13003

GSK Investigational Site, Marseille

13009

GSK Investigational Site, Marseille

14215

GSK Investigational Site, Buffalo

15006

GSK Investigational Site, A Coruña

16138

GSK Investigational Site, Genoa

19104

GSK Investigational Site, Philadelphia

19107

GSK Investigational Site, Philadelphia

20007

GSK Investigational Site, Washington D.C.

20009

GSK Investigational Site, Washington D.C.

20127

GSK Investigational Site, Milan

22003

GSK Investigational Site, Annandale

24127

GSK Investigational Site, Bergamo

27599

GSK Investigational Site, Chapel Hill

27710

GSK Investigational Site, Durham

28029

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

30308

GSK Investigational Site, Atlanta

30912

GSK Investigational Site, Augusta

32804

GSK Investigational Site, Orlando

33000

GSK Investigational Site, Bordeaux

33139

GSK Investigational Site, Miami Beach

33316

GSK Investigational Site, Fort Lauderdale

34982

GSK Investigational Site, Ft. Pierce

41013

GSK Investigational Site, Seville

43614

GSK Investigational Site, Toledo

45067

GSK Investigational Site, Orléans

50011

GSK Investigational Site, Bagno A Ripoli (FI)

50134

GSK Investigational Site, Florence

70506

GSK Investigational Site, Lafayette

75018

GSK Investigational Site, Paris

75204

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

75475

GSK Investigational Site, Paris

75651

GSK Investigational Site, Paris

75679

GSK Investigational Site, Paris

75743

GSK Investigational Site, Paris

75970

GSK Investigational Site, Paris

77004

GSK Investigational Site, Houston

77098

GSK Investigational Site, Houston

78705

GSK Investigational Site, Austin

89106

GSK Investigational Site, Las Vegas

90033

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

90211

GSK Investigational Site, Beverly Hills

92380

GSK Investigational Site, Garches

92708

GSK Investigational Site, Fountain Valley

93009

GSK Investigational Site, Bobigny

93602

GSK Investigational Site, Aulnay-sous-Bois

94109

GSK Investigational Site, San Francisco

95503

GSK Investigational Site, Gonesse

97210

GSK Investigational Site, Portland

98104

GSK Investigational Site, Seattle

92103-8208

GSK Investigational Site, San Diego

06510

GSK Investigational Site, New Haven

06850

GSK Investigational Site, Norwalk

02115

GSK Investigational Site, Boston

39216-4505

GSK Investigational Site, Jackson

07103

GSK Investigational Site, Newark

02906

GSK Investigational Site, Providence

V6Z 1Y6

GSK Investigational Site, Vancouver

V6Z 2C7

GSK Investigational Site, Vancouver

L8N 3Z5

GSK Investigational Site, Hamilton

M4N 3M5

GSK Investigational Site, Toronto

M4T 3A7

GSK Investigational Site, Toronto

M5B 1L6

GSK Investigational Site, Toronto

H2L 4P9

GSK Investigational Site, Montreal

H2L 5B1

GSK Investigational Site, Montreal

H2W 1T8

GSK Investigational Site, Montreal

H2X 2P4

GSK Investigational Site, Montreal

H3G 1A4

GSK Investigational Site, Montreal

06202

GSK Investigational Site, Nice

Unknown

GSK Investigational Site, Amadora

1349-019

GSK Investigational Site, Lisbon

1649-035

GSK Investigational Site, Lisbon

03010

GSK Investigational Site, Alicante

08916

GSK Investigational Site, Badalona

08036

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Shionogi

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT01328041 - A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. | Biotech Hunter | Biotech Hunter